within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02A_Antifibrinolytics.B02AB02_Alfa1Antitrypsin;

model Alfa1Antitrypsin
  extends Pharmacolibrary.Drugs.ATC.B.B02AB02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B02AB02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alfa1 antitrypsin (AAT) is a serine protease inhibitor primarily used for the treatment of alpha-1 antitrypsin deficiency, a hereditary disorder that can lead to emphysema and chronic obstructive pulmonary disease (COPD). It is administered as an augmentation therapy in individuals with severe deficiency of this protein. The drug is approved for clinical use today, especially in patients exhibiting clinical evidence of emphysema and low AAT levels.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult alpha1-antitrypsin deficient patients after intravenous administration of plasma-derived AAT; mixed-sex, stable state.</p><h4>References</h4><ol><li><p>Brantly, ML, et al., &amp; Veale, AG (2024). Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study. <i>Chronic obstructive pulmonary diseases (Miami, Fla.)</i> 11(3) 282–292. DOI:<a href=&quot;https://doi.org/10.15326/jcopdf.2023.0469&quot;>10.15326/jcopdf.2023.0469</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38809792/&quot;>https://pubmed.ncbi.nlm.nih.gov/38809792</a></p></li><li><p>Campos, MA, et al., &amp; Brantly, ML (2013). Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). <i>COPD</i> 10(6) 687–695. DOI:<a href=&quot;https://doi.org/10.3109/15412555.2013.800852&quot;>10.3109/15412555.2013.800852</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23862647/&quot;>https://pubmed.ncbi.nlm.nih.gov/23862647</a></p></li><li><p>Usmani, OS (2020). Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option. <i>Chronic obstructive pulmonary diseases (Miami, Fla.)</i> 7(3) 272–279. DOI:<a href=&quot;https://doi.org/10.15326/jcopdf.7.3.2019.0179&quot;>10.15326/jcopdf.7.3.2019.0179</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32726075/&quot;>https://pubmed.ncbi.nlm.nih.gov/32726075</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Alfa1Antitrypsin;
